blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3449944

EP3449944 - ORALLY ADMINISTERED NANOPARTICLES FOR GENE DELIVERY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  05.01.2024
Database last updated on 31.08.2024
FormerExamination is in progress
Status updated on  03.09.2021
FormerRequest for examination was made
Status updated on  01.02.2019
FormerThe international publication has been made
Status updated on  04.11.2017
Most recent event   Tooltip05.01.2024Application deemed to be withdrawnpublished on 07.02.2024  [2024/06]
Applicant(s)For all designated states
KB Biomed Inc.
Nano Bio Laboratory
Chemical Bio Hall
50 Daehak-ro
Chungju-si, Chungcheongbuk-do 27469 / KR
[2019/10]
Inventor(s)01 / LEE, Yong-Kyu
107-603
12 Yeonsudongsan-ro
Chungju-si Chungcheongbuk-do 27353 / KR
02 / LEE, Dong Yun
28-1701
113 Apgujeong-ro
Gangnam-gu
Seoul 06000 / KR
03 / KANG, Sung Hun
242
50 Daehak-ro Daesowon-myeon
Chungju-si Chungcheongbuk-do 27469 / KR
04 / VISHNU, Revuri
109-10 Modan-gil
Chungju-si Chungcheongbuk-do 27470 / KR
 [2019/10]
Representative(s)Schnappauf, Georg
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2019/10]
Application number, filing date17789915.026.04.2017
[2019/10]
WO2017KR04456
Priority number, dateKR2016005095526.04.2016         Original published format: KR 20160050955
[2019/10]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017188731
Date:02.11.2017
Language:KO
[2017/44]
Type: A1 Application with search report 
No.:EP3449944
Date:06.03.2019
Language:EN
[2019/10]
Search report(s)International search report - published on:KR02.11.2017
(Supplementary) European search report - dispatched on:EP03.12.2019
ClassificationIPC:A61K47/50, A61K47/28, A61K47/12, A61K9/00, A61K48/00
[2019/10]
CPC:
A61P3/10 (EP,US); A61K48/0041 (US); A61K47/12 (EP,KR,US);
A61K47/28 (EP,KR,US); A61K47/50 (EP,US); A61K48/00 (EP,KR,US);
A61K48/0075 (US); A61K9/00 (EP,US); A61K9/0053 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/10]
TitleGerman:ORAL VERABREICHTE NANOPARTIKEL ZUR GENVERABREICHUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT[2019/10]
English:ORALLY ADMINISTERED NANOPARTICLES FOR GENE DELIVERY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME[2019/10]
French:NANOPARTICULES À USAGE ORAL POUR L'ADMINISTRATION DE GÈNE ET COMPOSITION PHARMACEUTIQUE LES CONTENANT[2019/10]
Entry into regional phase26.10.2018Translation filed 
26.10.2018National basic fee paid 
26.10.2018Search fee paid 
26.10.2018Designation fee(s) paid 
26.10.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
26.10.2018Examination requested  [2019/10]
19.06.2020Amendment by applicant (claims and/or description)
02.09.2021Despatch of a communication from the examining division (Time limit: M04)
30.12.2021Reply to a communication from the examining division
26.04.2023Despatch of a communication from the examining division (Time limit: M04)
07.09.2023Application deemed to be withdrawn, date of legal effect  [2024/06]
27.09.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2024/06]
Fees paidRenewal fee
30.04.2019Renewal fee patent year 03
22.04.2020Renewal fee patent year 04
19.04.2021Renewal fee patent year 05
22.03.2022Renewal fee patent year 06
20.04.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO03017940  (ISIS PHARMACEUTICALS INC [US], et al) [X] 1,6-8,14,15 * [0010], [0012], [0020], [0028], [0031], [0044], [00131], [0133], [0014], [0050]-[0051];; claims 1-3,6, 9, 15-18 * [I] 5;
 [A]US2013095187  (HAHN SEI KWANG [KR], et al) [A] 1-15* the whole document *;
 [XI]WO2013185032  (HARVARD COLLEGE [US]) [X] 1-4,6-10,14,15 * [0070], [0073], [00222], ([0073]-[0075], [00190], [00298] point 47, [00298] point 57, [00133], [00298] point 2, [00172], [00298] point 9, ([00215], [0058], [00253];; claims 2, 9, 57 * [I] 5;
 [X]KR20140091133  (KOREA ADVANCED INST SCI & TECH [KR]) [X] 1,8,10 * [0012], [0015]-[0016], [0020], [0030], [0043]-[0044], [0054]-[0058], [0035];; claims 1-5, 11-13 *;
 [XP]WO2016070082  (UNIV UTAH RES FOUND [US], et al) [XP] 1-4,6-15 * [0002], [0055], [0057]-[0059], [0062], [0082], [0054], [0064], [0055], [0089], [0061], [0082], [0136], [0142], [0144], [0146], [0150], [0076], [0081], [0084], [0118], [0133], [0090]-[0091], [0096], [0087], [0112]-[0115];; claims 1-4, 10-11, 14-16 *
International search[XY]KR20100122405  (KOREA INST SCI & TECH [KR]) [X] 1-11, 13-16 * See abstract, paragraphs [0022], [0032]: and claims 1-3, 13, 14. * [Y] 12, 17, 18;
 [A]KR20110006188  (KOREA ELECTRONICS TELECOMM [KR]) [A] 1-18 * See the entire document. *;
 [A]KR20140107995  (CHONG KUN DANG PHARM CORP [KR]) [A] 1-18 * See the entire document. *;
 [A]KR20150021022  (ENGENE, INC.) [A] 1-18 * See the entire document. *;
 [PX]KR20160112164  (UNIV KOREA NAT TRANSP IND ACAD COOP FOUND [KR], et al) [PX] 1-11, 13-16* See paragraph 100141; claims 1-9; and figure 1. *;
 [Y]  - JEAN, M. et al., "Chitosan-based Therapeutic Nanoparticles for Combination Gene Therapy and Gene Silencing of in vitro Cell Lines Relevant to Type 2 Diabetes", European Journal of Pharmaceutical Sciences, (20120000), vol. 45, no. 1, pages 138 - 149, XP028341138 [Y] 12, 17, 18 * See abstract and page 140. *

DOI:   http://dx.doi.org/10.1016/j.ejps.2011.10.029
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.